TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Calcified NCC~* Perilesional edema on CT or MRI~* Normal lab values~Exclusion Criteria:~* Viable neurocysticercosis~* Status epilepticus~* Symptomatic intracranial hypertension~* Tuberculosis~* More than 7 days after seizure~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acetazolamide (Type: ACTIVE_COMPARATOR): 750 mg acetazolamide p.o. divided in three dily doses, for 10 days
- Dexamethasone (Type: ACTIVE_COMPARATOR): 8 mg p.o. divided in three daily daily doses, for 2 days followed by gradual tapering
- No additional anti-edema treatment (Type: NO_INTERVENTION): No additional treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of CD20+ chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with chemotherapy or chemoimmunotherapy: Post-frontline therapy, patients must have non-progressing disease and be 4 months to 1 year post treatment. Post-treatment for relapsed CLL, eligible patients must have non-progressing disease and be 3 months to 1 year post treatment.~2. Patients (CR, nPR, or PR at enrollment) must have measurable disease, which may include MRD by 4-color flow cytometry.~3. Adequate renal and hepatic function (creatinine \< 2 mg/dL, bilirubin \< 2 mg/dL). Patients with renal or liver dysfunction due to organ infiltration by lymphocytes may be eligible after discussion with the study chairman. Patients with Gilbert's syndrome are eligible.~4. Age \>/= 18 years.~5. ECOG performance status of 0-2.~6. Provide informed consent indicating patient is aware of the investigational nature of this study according to the policies of the MDACC IRB.~7. Patients of childbearing potential (females who have not been postmenopausal for at least 12 consecutive months or who have not undergone previous surgical sterilization or males who have not been surgically sterilized) must be willing to practice birth control during the study.~Exclusion Criteria:~1. Positive serology for Hepatitis B virus (HB) defined as a positive test for HBsAg. In addition, if negative for HBsAg but HBcAb positive (regardless of HBsAb status), a HB DNA test will be performed and if positive the subject will be excluded.~2. Concurrent chemotherapy, radiotherapy, or immunotherapy, including other monoclonal antibodies. Localized radiotherapy to an area not comprising bone marrow function does not apply.~3. Active infection or significant medical illness, including current active hepatic or biliary disease (with exception of patients with asymptomatic gallstones, liver involved with CLL or stable chronic liver disease per investigator assessment).~4. Pregnant and breastfeeding females are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ofatumumab (Type: EXPERIMENTAL): Ofatumumab 300 mg dose 1, then 1,000 mg weekly \* 7, (treatment) then 1,000 mg every 2 months beginning on week 12 for a total of 2 years of treatment or until progression (maintenance) of disease. The follow-up period will be the period after completion of maintenance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Patient Satisfaction and Visual Outcomes After Bilateral PanOptix Implantation in Patients With Previous Multifocal Contact Lens

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Subjects are eligible for the study if they meet the following criteria:~Note: Ocular criteria must be met in both eyes.~* Adult cataract patients undergoing uncomplicated cataract surgery with Clareon PanOptix IOL implantation (non-toric/toric).~* Visually significant cataracts bilaterally.~* History of successful soft multifocal contact lens use in the past (within ≤ last 5 years).~* Healthy ocular exam.~* Gender: Males and Females.~* Willing and able to provide written informed consent for participation in the study.~* Willing and able to comply with scheduled visits and other study procedures.~Exclusion Criteria:~If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.~* Previous monovision patients.~* Ocular comorbidity that might hamper post operative visual acuity (Uveitis, Keratoconus, Retinopathies, Glaucoma).~* Previous ocular or refractive surgery.~* Expected monocular post-op distance VA worse than 20/25 (Snellen) in either eye.~* Refractive lens exchange.~* Angle kappa measurement in a single eye over 0.6 mm.~* Irregular corneal astigmatism or ectasia.~* Difficulties comprehending written or spoken English language.~* Patients with physical or intellectual disability (e.g. Down's Syndrome, Parkinson's Disease; unable to fixate).~* Severe/uncontrolled Ocular surface disease/Dry Eye Disease.~* Intraoperative complications during procedure.~* Visual expectations exceed outcomes.~* Strabismus (with or without amblyopia).~The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.~Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- The Clareon™ PanOptix™ Trifocal (toric and non-toric models) (Type: None): Bilateral implantation with the Clareon PanOptix Trifocal (toric and non-toric models)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Assess the Effect of Transfusion Strategies on Fatigability Levels After Hospital Discharge

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Hospitalized on a general medicine service at the University of Chicago~* Any hemoglobin (Hb) concentration \<9g/dL~Exclusion Criteria:~* Have sickle cell anemia~* Decline blood transfusion~* Are receiving palliative care treatment only~* Are brain dead~* Cannot follow up after hospital discharge

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liberal Transfusion Arm (Type: ACTIVE_COMPARATOR): Patient's in the liberal transfusion arm will receive a 1 unit RBC transfusion following randomization and will re-ceive blood in additional 1 unit increments until their Hb is above 9g/dL. At any point during the patient's hospital-ization if their Hb subsequently falls below 9g/dL, they will again be transfused to maintain a Hb\>9g/dL, and this will be maintained throughout their hospitalization.
- Restrictive Transfusion Arm (Type: ACTIVE_COMPARATOR): Patients in the restrictive transfusion arm will receive transfusion if their Hb concentration falls below 7g/dL. RBC's will be administered 1 unit at a time and enough blood will be given to increase patient's Hb to above 7g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Scan Ultrasonography in the Evaluation of Retinopathy of Prematurity

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* neonates being screened for retinopathy of prematurity~Exclusion Criteria:~* medically unstable neonates

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study Evaluating ET-01 in Subjects With Transfusion Dependent β-Thalassaemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects and/or legal representative fully understand and voluntarily sign informed consent forms.~* Diagnosis of transfusion dependent β-thalassemia (β-TDT) as defined by protocol.~* Be not appropriate to receive conventional allogeneic hematopoietic stem cell transplantation.~* Lansky/Karnofsky score ≥ 70%.~* Eligible for hematopoietic stem cell transplantation and conditioning with busulfan as per investigator's judgement.~Other protocol defined inclusion criteria may apply.~Key Exclusion Criteria:~* Subjects with associated α-thalassemia.~* Subjects with any clinically significant acute or uncontrolled infections.~* History of uncontrolled epilepsy or other mental disorders.~* Previous treatment with allogeneic bone marrow transplantation or gene therapy.~Other protocol defined exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- ET-01 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of EXPAREL® on Postsurgical Pain, and the Use of Narcotics

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female~* 18-72 years of age~* Subjects scheduled to undergo a rotator cuff repair with a subacromial decompression by one of the protocol investigators~Exclusion Criteria:~* Planned concomitant glenoid labral repair~* Previous open shoulder surgery~* Neurological deficit or other disability involving the surgical extremity~* Anyone with a documented allergy to bupivicaine~* Subjects that are not mentally competent to give consent~* Pregnant women~* Subjects with an intolerance to hydrocodone or oxycodone and/or brand name equivalent combination medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- EXPAREL 1.3 % in 20 ML Injection (Type: OTHER): EXPAREL (bupivacaine liposome injectable suspension, 20 mL single use vial, 1.3% \[13.3 mg/mL\]) is a liposome injection of bupivacaine, an amide local anesthetic, indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. EXPAREL dosage is based on the following factors:~* size of surgical site~* volume required to cover the area~* individual patient factors that may impact the safety of an amide local anesthetic~* maximum doe of 266 mg (20 mL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of uncomplicated neonatal gastroschisis treated by primary fascial closure or delayed closure using a pre-formed silo (fascial closure or plastic closure)~2. Expectation of the treating physician that the patient will require intravenous therapy for at least 7 days post-enrolment~Exclusion Criteria:~1. Presence of other significant congenital malformation (ie life-threatening, requiring surgical intervention, or having an effect on intestinal motility)~2. Presence of intestinal atresia, intestinal necrosis or intestinal perforation (ie complicated gastroschisis)~3. Gestational age \<32 weeks~4. Birth weight \< 1500 gm~5. Received an investigational product within the past 30 days

- Gender: ALL
- Minimum Age: 33 Weeks
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intravenous metoclopramide (Type: EXPERIMENTAL): the experimental arm will receive intravenous metoclopramide
- control arm (Type: PLACEBO_COMPARATOR): the control arm will receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologic confirmation of non-small-cell lung cancer~* Stable systemic disease~* Maximum of one prior chemotherapy regimen for metastatic systemic disease~* Radiotherapy for local control or palliative bony lesions is allowed~* Karnofsky of greater than or equal to 70%~* Adequate hematologic, renal and liver function~Exclusion Criteria:~* Patients eligible for surgery of the brain~* Any previous chemotherapy for the brain metastasis~* Chemotherapy within 4 weeks or previous temozolomide~* Prior radiotherapy to the brain~* Radiation therapy to greater than 50% of the bone marrow~* Insufficient recovery from previous therapies~* Active nonmalignant systemic disease~* Inability to take oral medication~* Pregnant or nursing women~* Non use of adequate contraceptive techniques, negative urine pregnancy test is required~* Known AIDS related illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Vitamin D on Renin Expression in Hypertensive Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients age \> 55 years.~2. Female patients must be postmenopausal, as determined by surgical hysterectomy or 12 month history since last active menstruation~3. Stage I hypertension (JNC VII Criteria): mean systolic blood pressure (mSBP) 140-159 mmHg and mean diastolic blood pressure 90 - 99 mmHg (mDBP)2~4. Provide informed consent~Exclusion Criteria:~1. Serum vitamin D \<55 pmol/L~2. Serum calcium \>10.5 mg/dL~3. Serum phosphate (inorganic) \>5.5 mg/dL~4. Serum parathyroid hormone (PTH) \>1.3 pmol/L~5. Vitamin D supplements, calcium supplements, estrogen replacement therapy, corticosteroids (inhaled/oral), or hydroxymethyl glutarate CoA reductase inhibitors (statins) within 30 days prior to randomization~6. Stage II hypertension (JNC VII criteria): mSSBP \>160 mmHg or mSDBP \>100 mmHg~7. Use of alpha2-agonists, beta-blockers, or more than 2 anti-hypertensive medications at screening~8. Estimated creatinine clearance \<30 mL/min by Crockroft-Gault Formula~9. History of heart failure (HF), acute myocardial infarction (AMI), acute coronary syndrome (ACS), transient ischemic attack (TIA), cerebrovascular accident (CVA), peripheral vascular disease (PVD), or known clotting disorder~10. Insulin dependent diabetes mellitus (patients stabilized on oral regimens may be enrolled)~11. History of hypersensitivity reaction to 1α, 25-(OH)2 vitamin D3 (calcitriol)

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Calcitriol (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Proof-of-Concept Study of Darbepoetin Alfa in Partial Correction of Anemia in Chinese With Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged above 20 years old~* Patients with Type 1 or Type 2 diabetes mellitus~* Estimated glomerular filtration rate less than 59 mL/min/1.73m2~* Patients not on renal replacement therapy~* Hemoglobin level at baseline : women less than 9.5 g/dL (inclusive) and men less than 10.5 g/dL (inclusive)~* All patients should be on a stable dose of the following medications 4 weeks before enrolment :~* Aspirin 80mg daily unless contraindicated~* Statin to achieve stable and optimal LDL-cholesterol level~* Maximal tolerated dose of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers~* Anti-hypertensive treatment to maintain blood pressure target of less than 130/80 mmHg or a level achieved without undue side effects~* Oral anti-diabetic drugs or insulin to maintain HbA1C less than 9.5%~Exclusion Criteria:~* Pregnancy, breast feeding or patient has plans of becoming pregnant during the study period~* Known non-diabetic renal disease~* Known cause of anemia not related to chronic kidney disease~* Presence of hemoglobinopathy~* History of pure red cell aplasia~* Known allergy to Darbepoetin alfa~* Severe liver impairment (\>= 3x ULN of ALT)~* Poorly controlled hypertension, systolic BP \>= 160mmHg or diastolic BP \>= 100mmHg~* Significant cardiovascular disease within 3 months of enrolment including acute coronary syndrome, cardiac revascularization procedure, transient ischemic attack and cerebrovascular accident~* History of major gastrointestinal bleeding in the 5 years prior to consent~* Investigational drugs within 30 days of enrolment~* Any other medical conditions that is considered as unsuitable for the study by investigator

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Receive Darbepoetin alfa
- 2 (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Infrared Pupillometry During General Anesthesia to Predict Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years undergoing arthroscopic knee surgery of any type~Exclusion Criteria:~* Blindness~* Anisocoria~* History of opioid abuse~* Chronic pain patients~* Gastric Reflux Disease (due to the use of laryngeal masks in the study)~* Non english speaking patients~* Cognitive impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Intervention Group (Type: EXPERIMENTAL): all enrolled patients undergo the same protocol/ treatment:~Anesthesia Premedication, Induction and Maintenance Pupillometry after administration of anesthetic drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Intervention~At the community-level, eligibility includes:~Inclusion Criteria:~* Location in Dosso, Tahoua, Maradi, Zinder, or Tillabéri regions~* Distinguishable from neighboring communities~* Verbal consent of community leader(s)~Exclusion criteria:~* Inaccessible or unsafe for study team~* Quartier designation on national census~At the individual-level, eligibility includes:~Inclusion criteria:~* Age 1-11 months~* Primary residence in a study community~* Verbal consent of caregiver/guardian for study participation~Exclusion criteria:~* Known allergy to macrolides~Population-based sample collections~At the community-level, eligibility includes:~Inclusion criteria:~* Location in study region~* Distinguishable from neighboring communities~* Verbal consent of community leader(s)~Exclusion criteria:~* Inaccessible or unsafe for study team~* Included in MORDOR trials~* Not randomly selected~At the individual-level, eligibility includes:~Inclusion criteria:~* Age 1-59 months or 7-12 years or caregiver/guardian of a child eligible for treatment~* Primary residence in a study community selected for sample collections~* Verbal consent of caregiver/guardian for study participation~Exclusion criteria:~* Not on list of randomly selected participants from the census

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Programmatic azithro 1-11 (Type: ACTIVE_COMPARATOR): Biannual oral azithromycin administration to children aged 1-11 months distributed by community health workers
- no intervention (Type: NO_INTERVENTION): No additional intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy